Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

Monotherapy with DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues frequently failed to maintain blood glucose in patients with type 2 diabtes. It was critical to determine which was more suitable of acarbose versus metformin plus pioglitazone.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing First Hospital, Nanjing Medical University
• Treatments: Acarbose; Metformin; Pioglitazone

Criteria

Inclusion Criteria:

• Willing to participate in this present study;

• Patients with type 2 diabetes receiving stable monotherapy of DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues for more than 3 months;

• Screening glycated hemoglobin (HbA1c) between 7.0% and 10.0%;

• Regular diet and exercise;

• Body mass index (BMI) ≥ 18.5 kg/m2

Exclusion Criteria:

• Intolerance of metformin, pioglitazone and acarbose;

• Severe liver disease or elevated transaminases (2.5-fold the upper limit);

• Renal dysfunction or elevated creatinine (1.3-fold the upper limit);

• Systemic steroids therapy or other medication influencing cholesterol metabolism in the past 3 months;

• Infection or stress state in the past 4 weeks;

• Pregnancy or lactation;

• Patients otherwise adjudged by the investigator to be inappropriate for inclusion into the study.